Indian biosimilars guidelines go on stream amid implementation concerns
This article was originally published in Scrip
Executive Summary
India is set to implement its first set of guidelines on biosimilars next month, lending much-needed clarity to the approval pathway for such products, though concerns persist on whether the country's regulatory machinery is geared to implement these effectively.
You may also be interested in...
Here’s What Competition Looks Like In India’s Humira Biosimilars Market
Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.
Here’s What Competition Looks Like In India’s Humira Biosimilars Market
Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.